Kite Pharma Company Profile (NASDAQ:KITE)

About Kite Pharma (NASDAQ:KITE)

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KITE
  • CUSIP: N/A
  • Web: www.kitepharma.com
Capitalization:
  • Market Cap: $10.28 billion
  • Outstanding Shares: 57,181,000
Average Prices:
  • 50 Day Moving Avg: $179.11
  • 200 Day Moving Avg: $115.03
  • 52 Week Range: $39.82 - $179.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.41
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $32.14 million
  • Price / Sales: 319.87
  • Book Value: $12.43 per share
  • Price / Book: 14.46
Profitability:
  • EBITDA: ($341,060,000.00)
  • Net Margins: -1,117.44%
  • Return on Equity: -59.56%
  • Return on Assets: -48.86%
Debt:
  • Current Ratio: 9.01%
  • Quick Ratio: 9.01%
Misc:
  • Average Volume: 1.99 million shs.
  • Beta: 2.67
  • Short Ratio: 8.99
 

Frequently Asked Questions for Kite Pharma (NASDAQ:KITE)

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma, Inc. (NASDAQ:KITE) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.94) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.97) by $0.03. The firm earned $10.10 million during the quarter, compared to the consensus estimate of $9.59 million. Kite Pharma had a negative return on equity of 59.56% and a negative net margin of 1,117.44%. The business's revenue for the quarter was up 110.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.91) EPS. View Kite Pharma's Earnings History.

When will Kite Pharma make its next earnings announcement?

Kite Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Kite Pharma.

Where is Kite Pharma's stock going? Where will Kite Pharma's stock price be in 2017?

17 analysts have issued 12 month target prices for Kite Pharma's stock. Their forecasts range from $54.00 to $135.00. On average, they anticipate Kite Pharma's stock price to reach $93.20 in the next year. View Analyst Ratings for Kite Pharma.

What are analysts saying about Kite Pharma stock?

Here are some recent quotes from research analysts about Kite Pharma stock:

  • 1. Cowen and Company analysts commented, "Competitor Novartis is scheduled to present pivotal data from CTL019’s JULIET trial in." (6/7/2017)
  • 2. Jefferies Group LLC analysts commented, "The NHS published a mock technology appraisal analysis to assess the value of CAR T therapy and determine a value-based price. The study was conducted for young ALL and determined a price of ??530K ($649K) was justified. We view this price as an upper limit for Axi-Cel pricing, and raise our Axi-Cel price estimate to $300K (prev' $200K). We also decreased WACC to 13% (prev 15%) which was offset by moderating share to drive our new PT of $101." (3/16/2017)
  • 3. Canaccord Genuity analysts commented, "The Kochenderfer study for CAR-19 published in the Journal of Clinical Oncology showed 12 months' median duration of complete response, suggesting positive read-through generally speaking for ZUMA-1. Importantly, 11 of 12 complete responses (CRs) are still ongoing, suggesting the potential for very long-term remission. We believe the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit." (3/15/2017)
  • 4. Wedbush analysts commented, "KITE is poised to complete submission of the first BLA for a CAR-T therapy, but we believe slow adoption of the new treatment modality may blunt its first mover advantage, as CAR-T competition matures and treatment strategies evolve to address safety and efficacy challenges." (2/1/2017)

Who are some of Kite Pharma's key competitors?

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:

  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

How do I buy Kite Pharma stock?

Shares of Kite Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of Kite Pharma stock can currently be purchased for approximately $179.79.


MarketBeat Community Rating for Kite Pharma (NASDAQ KITE)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  586 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  842
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $93.20 (48.16% downside)
Consensus Price Target History for Kite Pharma (NASDAQ:KITE)
Price Target History for Kite Pharma (NASDAQ:KITE)
Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017WedbushUpgradeUnderperform -> NeutralLowView Rating Details
8/29/2017Canaccord GenuityDowngradeBuy -> HoldLowView Rating Details
8/28/2017GuggenheimDowngradeBuy -> Neutral$128.00LowView Rating Details
8/28/2017SunTrust Banks, Inc.DowngradeBuy -> HoldMediumView Rating Details
8/28/2017BTIG ResearchDowngradeBuy -> NeutralHighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$74.00LowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingBuy$121.00 -> $135.00LowView Rating Details
7/13/2017Maxim GroupDowngradeBuy -> Hold$88.00LowView Rating Details
7/4/2017Roth CapitalReiterated RatingBuy$93.00MediumView Rating Details
7/4/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
5/30/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/19/2017HC WainwrightReiterated RatingBuy$85.00MediumView Rating Details
5/15/2017Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformN/AView Rating Details
5/9/2017Goldman Sachs Group, Inc. (The)Boost Price TargetBuy$85.00 -> $89.00HighView Rating Details
3/13/2017Standpoint ResearchDowngradeBuy -> Hold$85.00LowView Rating Details
3/6/2017Royal Bank Of CanadaBoost Price TargetOutperform$85.00 -> $95.00N/AView Rating Details
3/2/2017Citigroup Inc.DowngradeBuy -> Neutral$62.00 -> $87.00N/AView Rating Details
2/22/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
9/27/2016Barclays PLCBoost Price TargetEqual Weight$60.00 -> $65.00N/AView Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Kite Pharma (NASDAQ:KITE)
Earnings by Quarter for Kite Pharma (NASDAQ:KITE)
Earnings History by Quarter for Kite Pharma (NASDAQ KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($2.14)N/AView Earnings Details
8/8/2017Q2 2017($1.97)($1.94)$9.59 million$10.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.68)($1.74)$8.85 million$9.80 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.75)($1.70)$5.74 million$4.90 millionViewListenView Earnings Details
11/9/2016Q316($1.68)($1.49)$4.94 million$7.34 millionViewListenView Earnings Details
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.90)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.85)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.63)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.41)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$1.16($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.16)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kite Pharma (NASDAQ:KITE)
2017 EPS Consensus Estimate: ($7.72)
2018 EPS Consensus Estimate: ($7.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.79)($1.36)($1.60)
Q2 20175($1.93)($1.53)($1.76)
Q3 20175($2.26)($1.91)($2.09)
Q4 20175($2.49)($1.99)($2.27)
Q1 20182($2.26)($1.89)($2.08)
Q2 20182($2.26)($1.74)($2.00)
Q3 20182($2.21)($1.81)($2.01)
Q4 20182($1.96)($1.80)($1.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kite Pharma (NASDAQ:KITE)
Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 87.72%
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Arie BelldegrunChairmanSell26,347$179.66$4,733,502.02View SEC Filing  
9/25/2017Cynthia M ButittaCOOSell4,228$179.66$759,602.48View SEC Filing  
9/25/2017David D. ChangEVPSell7,927$179.66$1,424,164.82View SEC Filing  
9/25/2017Jeffrey WiezorekSVPSell5,283$179.66$949,143.78View SEC Filing  
9/25/2017Paul L. JenkinsonCFOSell948$179.66$170,317.68View SEC Filing  
9/25/2017Shawn TomaselloInsiderSell4,203$179.66$755,110.98View SEC Filing  
8/10/2017Cynthia M ButittaCOOSell15,000$120.72$1,810,800.00View SEC Filing  
8/10/2017Helen Susan KimEVPSell6,251$120.09$750,682.59View SEC Filing  
8/8/2017Helen Susan KimEVPSell79,949$119.56$9,558,702.44View SEC Filing  
8/3/2017Timothy L MooreEVPSell6,000$110.06$660,360.00View SEC Filing  
8/1/2017Timothy L MooreEVPSell12,000$107.69$1,292,280.00View SEC Filing  
7/31/2017Helen Susan KimEVPSell26,649$109.28$2,912,202.72View SEC Filing  
7/10/2017Cynthia M ButittaCOOSell15,000$103.09$1,546,350.00View SEC Filing  
7/3/2017Jeffrey WiezorekSVPSell10,000$104.32$1,043,200.00View SEC Filing  
6/26/2017Owen N WitteDirectorSell25,000$100.30$2,507,500.00View SEC Filing  
6/23/2017Cynthia M ButittaCOOSell5,000$100.81$504,050.00View SEC Filing  
6/16/2017Farah ChampsiDirectorSell20,450$89.79$1,836,205.50View SEC Filing  
6/14/2017Steven B RuchefskyDirectorSell20,000$89.48$1,789,600.00View SEC Filing  
6/9/2017Cynthia M ButittaCOOSell10,000$88.55$885,500.00View SEC Filing  
6/8/2017Roy DoumaniDirectorSell15,000$84.48$1,267,200.00View SEC Filing  
5/10/2017Paul L. JenkinsonCFOBuy3,450$72.59$250,435.50View SEC Filing  
5/9/2017Arie BelldegrunChairmanBuy17,000$68.57$1,165,690.00View SEC Filing  
5/9/2017David BondermanDirectorBuy50,000$68.94$3,447,000.00View SEC Filing  
5/1/2017David D ChangEVPSell20,000$82.09$1,641,800.00View SEC Filing  
4/28/2017Farah ChampsiDirectorSell19,168$82.75$1,586,152.00View SEC Filing  
4/26/2017Farah ChampsiDirectorSell123,913$82.67$10,243,887.71View SEC Filing  
4/25/2017Cynthia M ButittaCOOSell15,000$81.85$1,227,750.00View SEC Filing  
4/25/2017Farah ChampsiDirectorSell46,783$82.80$3,873,632.40View SEC Filing  
4/24/2017Farah ChampsiDirectorSell25,818$82.34$2,125,854.12View SEC Filing  
4/17/2017Farah ChampsiDirectorSell115,376$82.42$9,509,289.92View SEC Filing  
4/3/2017Cynthia M ButittaCOOSell5,000$81.96$409,800.00View SEC Filing  
4/3/2017Helen Susan KimEVPSell2,400$81.80$196,320.00View SEC Filing  
3/27/2017Cynthia M ButittaCOOSell10,000$77.67$776,700.00View SEC Filing  
3/15/2017Timothy L MooreEVPSell7,511$83.31$625,741.41View SEC Filing  
3/9/2017Cynthia M ButittaCOOSell21,118$80.78$1,705,912.04View SEC Filing  
3/1/2017Cynthia M ButittaCOOSell38,882$73.46$2,856,271.72View SEC Filing  
3/1/2017Helen Susan KimEVPSell50,300$67.78$3,409,334.00View SEC Filing  
3/1/2017Jeffrey WiezorekSVPSell18,000$75.01$1,350,180.00View SEC Filing  
3/1/2017Roy DoumaniDirectorSell18,800$74.46$1,399,848.00View SEC Filing  
2/27/2017Cynthia M ButittaCOOSell10,000$54.42$544,200.00View SEC Filing  
1/31/2017Cynthia M ButittaCOOSell10,000$50.56$505,600.00View SEC Filing  
1/6/2017Cynthia M ButittaCOOSell10,000$50.13$501,300.00View SEC Filing  
1/6/2017Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
12/20/2016Arie BelldegrunChairmanSell3,493$50.86$177,653.98View SEC Filing  
12/20/2016Cynthia M ButittaCOOSell2,482$50.86$126,234.52View SEC Filing  
12/20/2016David D. ChangEVPSell1,788$50.86$90,937.68View SEC Filing  
12/20/2016Jeffrey WiezorekSVPSell716$50.86$36,415.76View SEC Filing  
12/20/2016Shawn TomaselloInsiderSell4,901$50.86$249,264.86View SEC Filing  
12/1/2016Jeffrey WiezorekSVPSell1,500$50.76$76,140.00View SEC Filing  
11/25/2016Cynthia M ButittaCOOSell10,000$50.40$504,000.00View SEC Filing  
10/3/2016Jeffrey WiezorekSVPSell1,500$54.81$82,215.00View SEC Filing  
9/26/2016Cynthia M ButittaCOOSell10,000$54.13$541,300.00View SEC Filing  
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.00View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.00View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Kite Pharma (NASDAQ:KITE)
Latest Headlines for Kite Pharma (NASDAQ:KITE)
Source:
DateHeadline
seekingalpha.com logoQ3 Roundup: Top 5 Performing Knives
seekingalpha.com - October 16 at 5:09 AM
investorplace.com logoGilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
investorplace.com - October 13 at 10:34 AM
msn.com logoImmunotherapy Treatments for Cancer Gain Momentum
www.msn.com - October 13 at 6:14 AM
seekingalpha.com logoVertex Pharmaceuticals: Excellence In Cystic Fibrosis, Strong Potential Ahead
seekingalpha.com - October 10 at 7:42 PM
streetinsider.com logoForm 4 Kite Pharma, Inc. For: Oct 03 Filed by: Peacock Jonathan M - StreetInsider.com
www.streetinsider.com - October 7 at 1:36 AM
businesswire.com logoGilead Sciences Completes Acquisition of Kite Pharma, Inc. - Business Wire (press release)
www.businesswire.com - October 5 at 6:33 AM
finance.yahoo.com logoGilead Sciences: 'We Don't Think That His Departure Is a Red Herring'
finance.yahoo.com - October 2 at 12:36 PM
finance.yahoo.com logoBetter Buy: Gilead Sciences, Inc. vs. Pfizer
finance.yahoo.com - October 2 at 12:36 PM
finance.yahoo.com logoHere's Why Bluebird Bio (BLUE) Stock Is Falling Today
finance.yahoo.com - October 2 at 12:36 PM
americanbankingnews.com logo Brokerages Anticipate Kite Pharma, Inc. (KITE) Will Announce Earnings of -$2.13 Per Share
www.americanbankingnews.com - October 2 at 10:26 AM
reuters.com logoExclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources
www.reuters.com - September 30 at 12:13 AM
investopedia.com logoWhy Biotech and Tech Will Push Stocks Higher In 4Q
www.investopedia.com - September 29 at 2:07 PM
prnewswire.com logoDaily Technical Summary Reports on Biotech Stocks -- Gilead Sciences, Kite ...
www.prnewswire.com - September 29 at 2:07 PM
streetinsider.com logoForm 4 Kite Pharma, Inc. For: Sep 25 Filed by: Tomasello Shawn
www.streetinsider.com - September 28 at 10:12 AM
americanbankingnews.com logoInsider Selling: Kite Pharma, Inc. (KITE) CFO Sells 948 Shares of Stock
www.americanbankingnews.com - September 27 at 10:32 PM
americanbankingnews.com logoKite Pharma, Inc. (KITE) Insider Shawn Tomasello Sells 4,203 Shares
www.americanbankingnews.com - September 27 at 10:30 PM
americanbankingnews.com logoInsider Selling: Kite Pharma, Inc. (KITE) EVP Sells 7,511 Shares of Stock
www.americanbankingnews.com - September 27 at 10:30 PM
americanbankingnews.com logoCynthia M. Butitta Sells 4,228 Shares of Kite Pharma, Inc. (KITE) Stock
www.americanbankingnews.com - September 27 at 10:30 PM
americanbankingnews.com logoKite Pharma, Inc. (KITE) EVP David D. Chang Sells 7,927 Shares
www.americanbankingnews.com - September 27 at 10:30 PM
americanbankingnews.com logoInsider Selling: Kite Pharma, Inc. (KITE) Chairman Sells 26,347 Shares of Stock
www.americanbankingnews.com - September 27 at 10:30 PM
americanbankingnews.com logoKite Pharma, Inc. (KITE) SVP Jeffrey Wiezorek Sells 5,283 Shares
www.americanbankingnews.com - September 27 at 10:30 PM
nasdaq.com logoKite Pharma Triples So Far in 2017: What's Driving the Rally?
www.nasdaq.com - September 27 at 6:09 PM
finance.yahoo.com logoWildcat Capital: Drew Tarlow, Len Potter, Family Office Of The Year
finance.yahoo.com - September 25 at 4:58 PM
finance.yahoo.com logoNow That Gilead's Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy?
finance.yahoo.com - September 25 at 4:58 PM
finance.yahoo.com logo[$$] Getting Ready for Gilead's CAR-T
finance.yahoo.com - September 25 at 4:58 PM
thestreet.com logoTempur Sealy Promotes Bhaskar Rao To Chief Financial Officer
www.thestreet.com - September 25 at 9:03 AM
americanbankingnews.com logoKite Pharma, Inc. (KITE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 23 at 10:48 AM
nasdaq.com logoPfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
www.nasdaq.com - September 22 at 11:54 AM
fool.com logoGilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors - Motley Fool
www.fool.com - September 21 at 3:49 PM
finance.yahoo.com logoWhy Gilead Sciences Is Flying High With Kite
finance.yahoo.com - September 21 at 3:48 PM
investopedia.com logoWhy Drug Stocks Will Outperform the S&P and Dow
www.investopedia.com - September 19 at 11:43 PM
americanbankingnews.com logoShort Interest in Kite Pharma, Inc. (KITE) Drops By 32.7%
www.americanbankingnews.com - September 15 at 1:28 AM
fool.com logoGilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move. - Motley Fool
www.fool.com - September 12 at 2:41 AM
nasdaq.com logoImplied Volatility Surging for Kite Pharma (KITE) Stock Options - Nasdaq
www.nasdaq.com - September 12 at 2:41 AM
prnewswire.com logoCryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel
www.prnewswire.com - September 5 at 5:04 PM
finance.yahoo.com logoBiotech Stocks Back in Favor: Will the Rally Continue?
finance.yahoo.com - September 5 at 5:03 PM
finance.yahoo.com logoGilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
finance.yahoo.com - September 5 at 5:03 PM
finance.yahoo.com logoWhy It's Useful To Know A Company's Competitors When Trading
finance.yahoo.com - September 5 at 5:03 PM
seekingalpha.com logoGilead's Plans To Acquire Kite Pharma Just Got Big-Time Validation From Novartis - Seeking Alpha
seekingalpha.com - September 3 at 12:10 AM
finance.yahoo.com logoKite Pharma Inc (KITE): FDA Approval of Kymriah Is Good News for the Future of Axi-cel - Yahoo Finance
finance.yahoo.com - September 2 at 2:56 AM
fool.com logo3 Reasons Gilead Sciences Jumped to Buy Kite Pharma - Motley Fool
www.fool.com - September 2 at 2:56 AM
prnewswire.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE - PR Newswire (press release)
www.prnewswire.com - September 1 at 1:51 AM
seekingalpha.com logoGilead's Acquisition Of Kite Pharma Relieves Shareholders' Ennui - Seeking Alpha
seekingalpha.com - September 1 at 1:51 AM
americanbankingnews.com logoFY2017 EPS Estimates for Kite Pharma, Inc. Raised by Analyst (KITE)
www.americanbankingnews.com - August 31 at 9:24 AM
nasdaq.com logoJuno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal - Nasdaq
www.nasdaq.com - August 31 at 6:40 AM
latimes.com logoFDA approves historic 'living drug' treatment to fight childhood leukemia - Los Angeles Times
www.latimes.com - August 31 at 6:40 AM
finance.yahoo.com logoGilead to Fly High with Kite Pharma Acquisition for $11.9B - Yahoo Finance
finance.yahoo.com - August 31 at 6:40 AM
americanbankingnews.com logoInvestors Buy Large Volume of Call Options on Kite Pharma (KITE)
www.americanbankingnews.com - August 31 at 2:46 AM
americanbankingnews.com logoKite Pharma Target of Unusually High Options Trading (KITE)
www.americanbankingnews.com - August 31 at 2:20 AM
rttnews.com logoKite Pharma Inc. (KITE) Leaped To A New High After Bought By Gilead
www.rttnews.com - August 29 at 8:27 PM

Social

Chart

Kite Pharma (KITE) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.